Literature DB >> 1613014

Issues in the use of benzodiazepine therapy.

T Roth1, T A Roehrs.   

Abstract

In selecting a hypnotic for the symptomatic management of insomnia, clinicians should look for those that most favorably balance sleep induction and sleep maintenance with potential adverse side effects. While all benzodiazepines have demonstrated efficacy in nocturnal sedation, the side effects of different compounds--and different doses of the same compound--vary greatly. The most common adverse effects associated with benzodiazepines are residual sedation, anterograde amnesia, and rebound insomnia, which are also related to the insomnia complaint itself. Therefore, careful evaluation of the dose of a benzodiazepine hypnotic is the key to effective treatment of insomnia without inducement of adverse effects. The most common side effects of hypnotics and their relation to drug dose are reviewed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1613014

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  14 in total

1.  Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men.

Authors:  Ka Lai Yee; Jacqueline McCrea; Deborah Panebianco; Wen Liu; Nicole Lewis; Tamara Cabalu; Steven Ramael; Rebecca E Wrishko
Journal:  Clin Drug Investig       Date:  2018-07       Impact factor: 2.859

Review 2.  Insomnia pharmacotherapy.

Authors:  Timothy Roehrs; Thomas Roth
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

3.  Zolpidem and triazolam do not affect the nocturnal sleep-induced memory improvement.

Authors:  Jaime Meléndez; Irina Galli; Katica Boric; Alonso Ortega; Leonardo Zuñiga; Carlos F Henríquez-Roldán; Ana M Cárdenas
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

4.  Benzodiazepines: more "behavioural" addiction than dependence.

Authors:  Carlos de las Cuevas; Emilio Sanz; Juan de la Fuente
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

Review 5.  Pharmacological treatment of insomnia.

Authors:  M Maczaj
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

6.  Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.

Authors:  Hong Sun; William P Kennedy; Darren Wilbraham; Nicole Lewis; Nicole Calder; Xiaodong Li; Junshui Ma; Ka Lai Yee; Susan Ermlich; Eric Mangin; Christopher Lines; Laura Rosen; Jeffrey Chodakewitz; Gail M Murphy
Journal:  Sleep       Date:  2013-02-01       Impact factor: 5.849

Review 7.  An assessment of short-acting hypnotics.

Authors:  W B Mendelson; B Jain
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

8.  Treatment of Late-life Insomnia.

Authors:  Christina S McCrae; Joseph M Dzierzewski; Daniel Kay
Journal:  Sleep Med Clin       Date:  2009-12-01

9.  The Importance of Residual Effects When Choosing a Hypnotic: The Unique Profile of Zaleplon.

Authors:  Gary K. Zammit; Jeffrey A. Kramer
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-04

10.  Zaleplon, A Novel Nonbenzodiazepine Hypnotic, Effectively Treats Insomnia in Elderly Patients Without Causing Rebound Effects.

Authors:  Sonia Ancoli-Israel; James K. Walsh; Richard M. Mangano; Masamoto Fujimori
Journal:  Prim Care Companion J Clin Psychiatry       Date:  1999-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.